OASMY (Vivesto AB) Marketable Securities: $3.28 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OASMY Vivesto AB OASMY
26 GF Score
Price $0.00
! 1 Warning Sign
View Full Analysis

What is Vivesto AB Marketable Securities?

Vivesto AB OASMY 26 Marketable Securities is $3.28 Mil as of Mar. 2026. GuruFocus rates OASMY with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Vivesto AB's Marketable Securities for the quarter that ended in Mar. 2026 was $3.28 Mil.

Vivesto AB's annual Marketable Securities declined from Dec. 2023 ($7.09 Mil) to Dec. 2024 ($2.87 Mil) and declined from Dec. 2024 ($2.87 Mil) to Dec. 2025 ($0.01 Mil).

Vivesto AB  (OTCPK:OASMY) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Vivesto AB Marketable Securities Related Terms

Vivesto AB Marketable Securities Historical Data

* Premium members only.

The historical data trend for Vivesto AB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivesto AB Marketable Securities Chart

Vivesto AB Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.83 12.82 7.09 2.87 0.01

Vivesto AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.24 0.31 0.05 0.01 3.28
OASMY
26GF Score
Vivesto AB OASMY
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivesto AB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $3.28 Mil mean?
Vivesto AB (OASMY) has a Marketable Securities of $3.28 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Vivesto AB and its competitors.
Is Vivesto AB's Marketable Securities too high?
Vivesto AB's current Marketable Securities is $3.28 Mil. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's Marketable Securities compare to ZTS and UTHR?
Vivesto AB's Marketable Securities of $3.28 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Vivesto AB and its competitors. Vivesto AB's current Marketable Securities is $3.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OASMY) has a current Marketable Securities of $3.28 Mil. The current Marketable Securities is $3.28 Mil. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Vivesto AB (OASMY), the current Marketable Securities is $3.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivesto AB Business Description

Other Exchanges VIVE:SwedenOMA:Germany
Address Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score

Get the complete analysis for OASMY

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price